Migrasomes derived from human umbilical cord mesenchymal stem cells: a new therapeutic agent for ovalbumin-induced asthma in mice

• hUCMSC-derived migrasomes significantly ameliorate airway inflammation and mucus production in an OVA-induced asthma mouse model. • Migrasomes reduce Th2 cytokine expression (IL-4, IL-5, IL-13) and inhibit dendritic cell activation, suggesting an immunomodulatory mechanism. • Inhibition of migrasome production impairs the anti-inflammatory effects of hUCMSCs, highlighting migrasomes as key mediators of MSC therapy. • Migrasomes can be delivered to the lung and taken up by dendritic cells in vivo and in vitro, supporting their potential as a cell-free therapeutic agent for asthma.